{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Assessments (Table 1). The same questionnaire used during the Baseline visit will be utilized', 'throughout the study.', '7.6.1.2.', 'TSQM-9', 'The Treatment Satisfaction Questionnaire for Medication (TSQM) will assess patient satisfaction', 'with treatment. The TSQM is a validated psychometric tool that provides a general measure of', 'patient satisfaction with medication. [12] Where available, the TSQM questionnaire will be', 'distributed to patients to self-complete as specified in the Schedule of Assessments (Table 1).', '7.6.1.3.', 'HAL', 'The Hemophilia Activities List (HAL) and the Pediatric HAL (pedHAL) questionnaires will', 'assess subjective functional ability to perform activities of daily living [13] The HAL will be', 'assessed in patients >18 years of age and the pedHAL will be assessed in patients <18 years of', 'age. Where available, the HAL questionnaire will be distributed to patients to self-complete as', 'specified in the Schedule of Assessments (Table 1).', '7.6.1.4.', 'EQ-5D-5L', 'The EQ-5D-5L is a standardized instrument for use as a measure of QOL outcome. [14] It', 'consists of a questionnaire pertaining to 5 dimensions (mobility, self-care, usual activities,', 'pain/discomfort, and anxiety/depression) and a visual analog scale. Scoring of the questionnaire', 'is based on 5 degrees of disability (none, slight, moderate, severe, or extreme). Scoring of the', 'visual analog scale is based on a visual scale ranging from 0 (worst imaginable health state) to', '100 (best imaginable health state). Higher scores indicate better health status. The', 'questionnaires will be completed by all patients as specified in the Schedule of Assessments', '(Table 1).', '7.6.2.', 'Weight-adjusted Consumption of Factor Concentrates', 'Factor concentrate dose will be recorded by the patient in the eDiary and reviewed by the', 'Investigator (and Sponsor or delegate) for the study duration to assess on-demand factor', 'concentrate use as treatment of breakthrough bleeding episodes. Weight adjustment will be', 'calculated programmatically.', '7.6.3.', 'HJHS', 'The HJHS is a tool for assessment of joint health in subjects with hemophilia. [15] Joint health', 'status will be assessed via the HJHS, as administered by a healthcare professional trained in the', 'use of anthropometric measures, as specified in the Schedule of Assessments (Table 1).', 'Completed HJHS score forms will be collected and archived according to the Study Manual.', '8.', 'STATISTICS', 'A Statistical Analysis Plan (SAP) will be finalized before database lock. The plan will detail the', 'implementation of the statistical analyses in accordance with the principal features stated in the', 'protocol.', 'Property of the Sanofi Group - strictly confidential', '66', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'The primary efficacy and safety analyses will be performed after all patients have either finished', 'the 9-month treatment period or discontinued from the study.', '8.1.', 'Determination of Sample Size', 'Assuming a mean ABR of 18 with standard deviation (SD) = 14 in the on-demand arm (patients', 'randomized to receive on-demand factor concentrates) and a mean ABR of no more than 4 with', 'SD = 6 in the fitusiran treatment arm (patients randomized to receive fitusiran) in either the', 'efficacy period or treatment period, with a sample size of 32 evaluable patients in on-demand', 'arm and approximately 64 evaluable patients in the fitusiran treatment arm, it is projected that', 'the study will have greater than 90% power for testing treatment difference in mean ABRs. This', 'power estimation was based on a negative binomial regression model with a 2-sided type I error', 'rate of 0.05.', 'The planned sample size is 120 randomized patients assuming a 20% drop-out rate.', '8.2.', 'Statistical Methodology', 'The statistical and analytical plans presented below are brief summaries of planned analyses.', 'More complete plans will be detailed in the SAP. Changes to the methods described in the final', 'SAP will be described and justified as needed in the clinical study report.', '8.2.1.', 'Populations to be Analyzed', 'The populations (analysis sets) are defined as follows:', 'Intent-to-treat (ITT) Analysis Set: All randomized patients. All by-treatment analyses', 'based on the ITT analysis set will be according to the randomized treatment arm.', 'Safety Analysis Set: All patients who received at least 1 dose of fitusiran or were', 'randomized to on-demand arm. All by-treatment analyses based on the safety', 'analysis set will be according to the actual treatment received.', 'Per-protocol Analysis Set: All patients in the ITT set who had no major protocol', 'deviations. Major deviations will be specified in the SAP.', 'PK Analysis Set: All patients who receive at least 1 dose of fitusiran and have at', 'least one postdose blood sample for PK parameters and who have evaluable PK data.', 'Operative Procedure Analysis Set: All patients who received at least 1 dose of', 'fitusiran and underwent at least 1 operative procedure during the study.', '8.2.2.', 'Examination of Subgroups', 'Exploratory subgroup analysis on ABR will be conducted for the primary endpoint and selected', 'secondary endpoints. Description of the subgroups will be specified in the SAP.', '8.2.3.', 'Handling of Missing Data', 'Handling of missing data will be described in the SAP.', 'Property of the Sanofi Group - strictly confidential', '67', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}